Comparison of efficacy of anagliptin and alogliptin for lipid profile between type 2 diabetic patients

Comparison of efficacy of anagliptin and alogliptin for lipid profile between type 2 diabetic patients - Comparison of efficacy of anagliptin and alogliptin for lipid profile

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018949

Enrollment

100

Registered

2015-09-08

Start date

2014-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

anagliptin subjects were allocated randomly by the envelope method to either of two treatment groups: anagliptin 200mg/day or alogliptin 25 mg/day(using DPP4 inhibitor was stopped). After 24-week ora

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetes using DPP-4 inhibitors except for anagliptin and alogliptin, presented with LDL-C above 120mg/dl. Participants provided their informed consent to participate in the study. Participants provided their informed consent to participate in the study.

Exclusion criteria

Exclusion criteria: Patients using glinide and insulin therapy, those who were or may have been pregnant, and those with severe renal dysfunction (s-Cre levels: male>1.4mg/dl, female>1.2mg/dl) were excluded.

Design outcomes

Primary

Measure	Time frame
change of LDL-C at 24 weeks	—

Countries

Japan

Contacts

Public ContactAkira Kurozumi

University of Occupational and Environmental Health First Department of Internal Medicine, School of Medicine

akira@med.uoeh-u.ac.jp0936031611

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026